BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)BALA CYNWYD, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates SSTK, ACCD, ESSA, AKYA on Behalf of ShareholdersNEW YORK, Jan. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Accolade, Inc. (NasdaqGS: ACCD) to Transcarent. Under the terms of the proposed transaction, shareholders of Accolade will receive $7.03 in cash for each share of Accolade that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Accolade Inc. (NASDAQ: ACCD) Leading the Way in Tuesday Trading Based on Percentage GainAccolade, Inc. (
NASDAQACCD) is one of today’s top gainers. The company’s shares have moved -0.61% on the day to $6.52.
Shareholder Alert: Ademi LLP Investigates Whether Accolade, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Ademi LLP is investigating Accolade (
NASDAQACCD) for possible breaches of fiduciary duty and other violations of law in its transaction with the Transcarent.
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Accolade, Inc. (
NASDAQACCD) to Transcarent for $7.03 per share in cash is fair to Accolade shareholders.
Transcarent To Acquire Accolade
Transcarent, the One Place for Health and Care, and Accolade (
NASDAQACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent will acquire Accolade for $7.03 per share in cash, which represents a total equity value of approximately $621M. This strategic combination, which has been unanimously approved by the Boards of Directors of both companies, will enhance Transcarent's mission to make it easy for people to access high-quality, affordable health and care. The combined platform will deliver a more personalized and engaging Member experience.
Transcarent To Acquire AccoladeCombined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment
Accolade Announces Results for Fiscal Second Quarter 2025SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal second quarter ended August 31, 2024.
Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (
NASDAQACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD.
Accolade, Inc. (ACCD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accolade, Inc. (“Accolade” or “the Company”) (
NASDAQACCD). Investors who purchased Accolade securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/ACCD.
ACCD Investors Have the Opportunity to Join Accolade, Inc. Securities Fraud Investigation with The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Accolade, Inc. (“Accolade” or “the Company”) (
NASDAQACCD) for violations of the securities laws.
Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2024SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal fourth quarter and full year ended February 29, 2024.
Accolade Announces Results for Fiscal Third Quarter 2024SEATTLE, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal third quarter ended November 30, 2023.
Accolade Announces Results for Fiscal Second Quarter 2024SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal second quarter ended August 31, 2023.
MarketBeat Week in Review – 7/10 - 7/14As inflation moderates, Investors are optimistic for the second quarter earnings season and that optimism is evident in some of the top stories from this week
Accolade: A Rising Personalized AI-Powered Healthcare PlatformAccolade Inc. (
NASDAQACCD) provides an artificial intelligence (AI)-powered healthcare platform. Learn more about Accolade Inc. stock.
Accolade Announces Results for Fiscal First Quarter 2024SEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal first quarter ended May 31, 2023.
Accolade Announces Results for Fiscal Fourth Quarter and Full Year 2023SEATTLE, April 27, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal fourth quarter and full year ended February 28, 2023.
Accolade Inc. (NASDAQ: ACCD) Records 52-Week High Thursday MorningShares of Accolade, Inc. (
NASDAQACCD) traded at a new 52-week high today and are currently trading at $16.56. So far today, approximately 272k shares have been exchanged, as compared to an average 30-day volume of 462.6k shares.
Accolade Inc. (NASDAQ: ACCD) Records 52-Week High Wednesday MorningShares of Accolade, Inc. (
NASDAQACCD) traded at a new 52-week high today and are currently trading at $14.72. So far today, approximately 192.23k shares have been exchanged, as compared to an average 30-day volume of 501.17k shares.
Accolade Announces Results for Fiscal Third Quarter 2023SEATTLE, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal third quarter ended November 30, 2022.
Accolade Announces Results for Fiscal Second Quarter 2023SEATTLE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Accolade, Inc. (
NASDAQACCD) today announced financial results for the fiscal second quarter ended August 31, 2022.
Priority Health announces launch of new health navigation solution, PriorityGPS™
Priority Health, a nationally recognized nonprofit health plan, announced today the launch of PriorityGPS™, an integrated health navigation and advocacy solution. PriorityGPS will be delivered through a strategic partnership with Accolade (Nasdaq: ACCD), a Personalized Healthcare service, and is available for self-funded (ASO), large employers.
Accolade Moves Higher But Growth Is SlowingAccolade (
NASDAQACCD) is certainly an interesting play on the health care space providing business and employee services geared toward helping clients navigate the cumbersome health benefits arena. The pandemic helped boost the company’s business and has on track to continue growing but there is a fly in the ointment.
